Cat. No. 0836
Chemical Name: 5-(Z)-7-(4-o-Hydroxyphenyl-2-triflu
Biological ActivityPotent thromboxane receptor antagonist.
Licensing InformationSold with the permission of AstraZeneca UK Ltd.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
on-line. Please contact Customer Service
Birch et al (1988) Studies in the guinea-pig with ICI 185,282: a thromboxane A2 receptor antagonist. J.Pharm.Pharmacol. 40 706. PMID: 2907537.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for ICI 185,282 include:
Kleinbongard et al (2011) Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 108 344. PMID: 21183739.
Do you know of a great paper that uses ICI 185,282 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: ICI 185,282, supplier, Potent, thromboxane, A2, TXA2, receptors, antagonists, TP, Prostanoid, prostaglandins, prostacyclins, eicosanoids, ICI185282, AstraZeneca, Tocris Bioscience, Prostanoid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppresentCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonistZQ 16
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonist
April 1 - 5, 2017
Washington, D.C., USA